Inovio Pharmaceuticals (INO) Investment in Debt & Equity (2020 - 2025)
Historic Investment in Debt & Equity for Inovio Pharmaceuticals (INO) over the last 6 years, with Q3 2025 value amounting to $2.5 million.
- Inovio Pharmaceuticals' Investment in Debt & Equity fell 561.59% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 561.59%. This contributed to the annual value of $1.6 million for FY2024, which is 4195.41% down from last year.
- As of Q3 2025, Inovio Pharmaceuticals' Investment in Debt & Equity stood at $2.5 million, which was down 561.59% from $3.1 million recorded in Q2 2025.
- Over the past 5 years, Inovio Pharmaceuticals' Investment in Debt & Equity peaked at $3.9 million during Q2 2021, and registered a low of $1.6 million during Q4 2024.
- For the 5-year period, Inovio Pharmaceuticals' Investment in Debt & Equity averaged around $2.8 million, with its median value being $2.6 million (2024).
- Its Investment in Debt & Equity has fluctuated over the past 5 years, first crashed by 4862.43% in 2022, then soared by 4060.62% in 2023.
- Inovio Pharmaceuticals' Investment in Debt & Equity (Quarter) stood at $3.9 million in 2021, then crashed by 48.62% to $2.0 million in 2022, then soared by 38.52% to $2.8 million in 2023, then plummeted by 41.95% to $1.6 million in 2024, then soared by 54.65% to $2.5 million in 2025.
- Its Investment in Debt & Equity stands at $2.5 million for Q3 2025, versus $3.1 million for Q2 2025 and $2.3 million for Q1 2025.